Ennova Technologies passes HKEX hearing: Accelerated productization and profit challenge for large model decision intelligence

```

On June 9, information disclosed by the Hong Kong Stock Exchange shows that Beijing Wenge Technology Co., Ltd. (“Wenge”) has published its post-hearing information pack and has officially passed the main board listing hearing. CICC serves as the sole sponsor.

At a time when the commercialization of general-purpose large models is progressing anxiously, this tech service provider focused on enterprise-level decision intelligence is about to face substantial scrutiny on the secondary market.

Unlike the commonly known general conversational large models, Wenge is focusing its main efforts on the more underlying decision intelligence area.

According to the prospectus, the company was founded by a team of scientists from the Institute of Automation, Chinese Academy of Sciences. Its core business relies on a self-developed Decision Intelligence Operating System (DIOS) that leverages AI-assisted decision-making, mainly empowering three major scenarios: public governance, media and communications, and commercial enterprises.

According to data from Frost & Sullivan, based on 2025 revenue, Wenge ranks first among domestic enterprise-level large model-driven decision intelligence service providers, with a market share of 10.2%.

It should be noted that the total national scale of this segment in 2025 is about 3.9 billion yuan, and the industry is still in the early stage of penetration and expansion. The company's leading position reflects a certain first-mover advantage.

Looking at operating data, Wenge has released some positive signals in business expansion and delivery efficiency. From 2023 to 2025, its revenue grew steadily from 249.7 million yuan to 405.3 million yuan, an increase of over 60%. Its gross margin climbed and stabilized at around 51.2% from 44.0%.

For AI service providers targeting B2B clients, productization capability is the core metric for evaluating the health of their business model. Two sets of operational data in the prospectus are particularly noteworthy:

The first is net revenue retention, which reached 139.5% in 2025. This means that payments from existing customers increased by nearly 40% year-on-year, indicating strong upsell and repurchase stickiness from the customer base.

The second is the delivery cycle: the average product deployment cycle shortened dramatically from 185 days in 2023 to 80.2 days in 2025.

The halving of the delivery cycle indirectly demonstrates that their underlying DIOS system is gradually achieving low-code and modular configuration capabilities. This shows the company is striving to break away from the traditional pitfalls of heavy outsourcing and excessive customization seen in AI enterprises, and its standardized service capability has improved.

However, behind the stable business growth, Wenge still faces the widespread financial pains of the current AI industry: persistently high R&D investment and the challenge to profitability fundamentals.

The technology iteration cycle in the large model and decision intelligence arena is extremely fast. From 2023 to 2025, Wenge's R&D expenses accounted for 71.9%, 41.2%, and 46.3% of revenue, respectively, with the absolute amount remaining high—an unavoidable cost to maintain technological barriers.

But such massive upfront R&D investment, coupled with relatively long payment cycles from public service clients, places stringent demands on company cash flow management.

Data shows that by the end of 2025, the company still recorded negative net operating cash flow of -188 million yuan, and its self-sustaining capacity remains to be proven.

Overall, Wenge’s successful hearing adds a target with both a strong research background and clear B-end application scenarios to the Hong Kong stock market. The company has already undergone several financing rounds, with endorsements from national-level funds and renowned investment institutions.

However, after truly landing in the capital market, whether the company can use the raised funds to further expand its commercial business, and strike a dynamic balance between high R&D expenditure and positive cash flow to reach break-even as soon as possible, will be the key factors for the market’s long-term valuation of the company.

Risk Warning and DisclaimerThe market has risks, and investment needs caution. This article does not constitute personal investment advice, nor does it take into account the particular investment objectives, financial situation, or needs of any individual user. Users should consider whether any opinions, views, or conclusions in this article are suitable for their specific situation. Any investment based on this is at your own risk. ```